Chigusa Morizane

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto et al. · Journal of Clinical Oncology · 2022 · 103 citations

Immunology, Pathology, Aggressive Tumor Biology +21

Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> fusions/rearrangements.

Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque et al. · Journal of Clinical Oncology · 2022 · 52 citations

Surgical Oncology, Foenix-cca2 Trial, Cancer Management +22

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial

Tetsuhide Ito, Takuji Okusaka, M. Ikeda et al. · Japanese Journal of Clinical Oncology · 2012 · 51 citations · Full text

Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study.

Junji Furuse, Masafumi Ikeda, Makoto Ueno et al. · Journal of Clinical Oncology · 2023 · 22 citations

Placebo-controlled Phase 2, Pathology, Pharmacotherapy +16